Ustekinumab – Treatment for Plaque Psoriasis
Key Data:
Drug (brand/generic)
Ustekinumab (CNTO 1275)
Company/licensee
Centocor and Janssen-Cilag
Therapy class
MAb
Product description
Human anti-IL-12 and anti-IL-23 MAb
Current indication
Moderate-to-severe plaque psoriasis
Market sector
Dermatology
Development status
Pre-registration US and Europe
